Financial

J&J’s sales of $17.1Bn for the third quarter of 2012, represent an increase of 6.5% compared to Q3 2011. Synthes product sales contributed 5.8% to worldwide operational sales growth, net of the divestiture of the DePuy trauma business.

SynCardia Systems, Inc., manufacturer of the world’s first and only FDA, Health Canada and CE approved Total Artificial Heart, announced today that revenue and implants for the first nine months of 2012 have exceeded the company’s best 12-month totals to date.
PR Newswire (http://s.tt/1pMln)

Edwards’ critical care portfolio expands to Include non-Invasive platform with the acquisition of Dutch monitoring company BMEYE.

Surgical Innovations has issued its 6 month financials which suggest the company has plenty of reasons to be cheerful as it looks forward to the fruits of new product approvals and distribution agreements in the U.S.

Stryker corporation is a big device player with orthopaedics, spine and neuro business to name three. Yet it’s European effort continues to result in falling share and disappointment. Recent management changes haven’t yet borne fruit, but the company is expecting better times ahead. While the medtech business can be a complicated affair, we suggest basic business principles still surely apply.

St.Jude has taken the radical decision to shoe-horn its previous four divisions into two. These will be called the Implantable Electronic Systems Division (IESD), which will encompass CRM and Neuromodulation, and the Cardiovascular and Ablation Technologies Division (CATD), which will encompass Atrial Fibrillation and Cardiovascular. 300 job cuts and a host of efficiency savings are anticipated.

Before we saw the numbers we were backing the line that it would be stents up, pacing and spine down, and so it came to pass. Medtronic’s numbers show the importance of emerging markets and contributions from its newly acquired businesses as the company posts 5% revenue gains.

SynCardia Systems, Inc., manufacturer of the world’s first and only FDA, Health Canada and CE approved Total Artificial Heart, has announced revenue for the quarter ended June 30, 2012, marking the company’s best quarter to date and its fifth consecutive profitable quarter.

TranS1’s technology is intriguing enough to keep on capturing our attention, but its revenue and gross margin picture for Q2 2012 are not painting a picture of growth. Encouraging words from the boss though.

HeartWare International Inc. has announced revenue of $29.1 million for the second quarter ended June 30, 2012, representing a 42 percent increase from $20.4 million in revenue for the same period of 2011. However the company recorded a net loss more than double prior year as it invested in R&D and commercialisation activity.

Financial key performance indicators for S&N’s quarter, when set against the equivalent period a year ago show revenue of $1,029 million, up 2% on an underlying basis, trading profit of $234 million, up 6% on an underlying basis, with trading profit margin up 80 bps to 22.7% as Advanced Surgical Devices (ASD) division restructuring benefits come through

Georgia’s Mimedx Group is a developer of biomaterial solutions for surgical repair of soft tissues using human amniotic membrane. Pretty specialised field and never likely to be sponsoring the Olympics, but nonetheless the company’s recently stated Q2 financials suggest it’s in good shape, having grown consistently and turned red numbers black in the past twelve months.

Edwards Lifesciences Corporation has released its second quarter financial results which are, on face value, bucking the trend by showing sales growth of almost 16% (albeit excluding currency impact) to $482m compared with the equivalent period last year. Closer examination reveals that growth is almost exclusively related to the company’s Sapien transcatheter heart valve, launched in U.S and seeing continued growth internationally.

Baxter International Inc. has announced financial results for the second quarter and confirmed its full-year 2012 financial outlook. Sales increase of 4% year-on-year coupled with 1% income hike is in line with previous guidance.

Stryker Corporation has reported its operating results for the second quarter of 2012 with net sales of $2.1 billion, up 2.9%. Neurotechnology and Spine divisional sales showed greatest percentage growth, although all divisions were up over the equivalent quarter a year ago.

Abbott has announced its financial results for the second quarter ended June 30, 2012. Reported sales increased 2.0 percent, including an unfavourable 4.7 percent effect of foreign exchange. Stent sales suffered due to the wind-down of the supply arrangement with Boston Scientific, but recent Xience news gives reason for optimism.